CEACAM5 inhibits the lymphatic metastasis of head and neck squamous cell carcinoma by regulating epithelial–mesenchymal transition via inhibiting MDM2
Open Access
- 25 November 2022
- journal article
- research article
- Published by Portland Press Ltd. in Clinical Science
- Vol. 136 (22), 1691-1710
- https://doi.org/10.1042/cs20220581
Abstract
Lymph node (LN) metastasis affects both the management and prognosis of head and neck squamous cell carcinoma (HNSCC). Here, we explored the relationship between lymphatic metastasis and CEA family member 5 (CEACAM5), including its possible regulatory role in HNSCC. The levels of CEACAM5 in tissues from patients with HNSCC, with and without LN metastases, were assessed by transcriptome sequencing. The associations between CEACAM5 and the N stage of LN metastasis in HNSCC were predicted through The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases and a pan-cancer analysis of CEACAM5 expression in 33 common human tumors was conducted. CEACAM5 levels were analyzed in tumor and normal tissue specimens from HNSCC patients and the correlation between CEACAM5 levels and prognosis was evaluated. The influence of CEACAM5 on cell proliferation, invasion, migration, and apoptosis was investigated in HNSCC cell lines, as were the downstream regulatory mechanisms. A mouse model of LN metastasis was constructed. CEACAM5 levels were significantly higher in HNSCC tissue without LN metastasis than in that with LN metastasis. Similar findings were obtained for the clinical specimens. CEACAM5 levels were associated with better clinical prognosis. CEACAM5 was found to inhibit the proliferation and migration and promote the apoptosis of HNSCC cells. A mouse xenograft model showed that CEACAM5 inhibited LN metastasis. In conclusions, CEACAM5 inhibited epithelial–mesenchymal transition in HNSCC by reducing murine double minute 2 (MDM2) expression and thereby suppressing LN metastasis. CEACAM5 has potential as both a prognostic marker and a therapeutic target in HNSCC.Keywords
This publication has 62 references indexed in Scilit:
- Regulatory networks defining EMT during cancer initiation and progressionNature Reviews Cancer, 2013
- MDM2, MDMX and p53 in oncogenesis and cancer therapyNature Reviews Cancer, 2013
- Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patientsInternational Journal of Cancer, 2011
- p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of SlugNature, 2009
- MDM2 Promoter SNP309 Is Associated with Risk of Occurrence and Advanced Lymph Node Metastasis of Nasopharyngeal Carcinoma in Chinese PopulationClinical Cancer Research, 2007
- Recent Advances in the Tumour Biology of the GPI-Anchored Carcinoembryonic Antigen Family Members CEACAM5 and CEACAM6Current Oncology, 2007
- Inhibition of Adhesion, Invasion, and Metastasis by Antibodies Targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen)Cancer Research, 2005
- Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction NetworksGenome Research, 2003
- Inhibiting the p53–MDM2 interaction: an important target for cancer therapyNature Reviews Cancer, 2003
- Carcinoma of the hypopharynxThe American Journal of Surgery, 1976